Table 1.
Comparison of selected clinically-available long-acting injections and candidate injections under clinical development
| Technology | Drug name | Route | Dosing interval | Condition | Clinical depot volume |
|---|---|---|---|---|---|
| Suspension-based | |||||
| Solid drug particle | Medroxyprogesterone acetate | SC | 3 monthly | Hormone therapy | 0.65 mL |
| Solid drug particle | Medroxyprogesterone acetate | IM | 3 monthly | Hormone therapy | 1 mL |
| Solid drug particle | Olanzapine | IM | 2-4 weekly | Schizophrenia | max. 2.7 mL |
| Solid drug particle | Paliperidone palmitate | IM | 1 monthly | Schizophrenia | max. 1.5 mL |
| Solid drug particle | Paliperidone palmitate | IM | 3 monthly | Schizophrenia | max. 2.7 mL |
| Microparticle/microsphere | Somatropin | SC | 2-4 weekly | Hormone therapy | max. 1.5 mL |
| Microparticle/microsphere | Leuprolide acetate | IM | 1-3 monthly | Prostate cancer | 1.5 mL |
| Microparticle/microsphere | Naltrexone | IM | 1 monthly | Alcohol dependence | 4 mL |
| Microparticle/microsphere | Risperidone | IM | 2 weekly | Schizophrenia | 2 mL |
| Solid drug particle (undergoing human trials)* | Cabotegravir | IM | 1 quarterly* | HIV therapy and PreP | 2 × 2mL split* |
| Solid drug particle (undergoing human trials)* | Rilpivirine | IM | 1 monthly* | HIV therapy and PreP | 2 × 2mL split* |
| Solution-based | |||||
| Oil-based | Flupenthixol decanoate | IM | 2-4 weekly | Schizophrenia | max. 2 mL |
| Oil-based | Zuclopenthixol decanoate | IM | 2-4 weekly | Schizophrenia | max. 3 mL |
| Oil-based | Testosterone cypionate | IM | 2-4 weekly | Hormone therapy | max. 1.5 mL |
| Oil-based | Estradiol valerate | IM | 1 monthly | Hormone therapy | max. 1 mL |
| In-situ implant | Leuprolide acetate | SC | 1-6 monthly | Prostate cancer | 0.375 mL |
| Early stage solution-based immunotherapies | |||||
| Aqueous concentrated protein (undergoing human trials)* | CCR5 Monoclonal Antibody (PRO-140) | SC | 1-2 weeks* | HIV | 2 × 1mL split* |
| Aqueous concentrated protein (undergoing human trials)* | Broadly neutralising monoclonal antibody (VRC01) | SC | 3-4 weekly* | HIV | TBD |
| Aqueous concentrated protein (undergoing human trials)* | Broadly neutralising monoclonal antibody (VRC01) | IV | 3-4 weekly* | HIV | NA‡ |
| Aqueous concentrated protein (undergoing human trials)* | Anti-CD4 binding site monoclonal Antibody (3BNC117) | IV | 1 monthly* | HIV | NA‡ |
*
Note that since these formulations are currently still in clinical development, dosing interval and volume should be considered subject to change.
‡
Intravenous infusions have shown long-acting benefits but are not considered depot injections